Dashboard
Poor long term growth as Net Sales has grown by an annual rate of 3.93% and Operating profit at 4.98% over the last 5 years
The company declared very negative results in Mar'25 after flat results in Dec'24
With ROCE of 5.38%, it has a very expensive valuation with a 1.57 Enterprise value to Capital Employed
Below par performance in long term as well as near term
Stock DNA
Chemicals & Petrochemicals
USD 4,628 Million (Small Cap)
126.00
NA
210.09%
0.66
2.46%
1.96
Total Returns (Price + Dividend) 
Avient Corp. for the last several years.
Risk Adjusted Returns v/s 
News

Avient Corp. Experiences Revision in Its Stock Evaluation Amid Premium Valuation Metrics
Avient Corp. has adjusted its valuation, showcasing a high P/E ratio of 126 and a price-to-book value of 1.97. Despite a low return on equity of 1.57%, the company boasts an unusually high dividend yield of 212.24%, distinguishing it within the Chemicals & Petrochemicals sector.
Read MoreIs Avient Corp. overvalued or undervalued?
As of 24 October 2025, the valuation grade for Avient Corp. has moved from expensive to very expensive, indicating a significant deterioration in its valuation standing. The company is overvalued based on its current metrics, with a P/E ratio of 126, a Price to Book Value of 1.97, and an EV to EBITDA of 14.53. In comparison, peers such as Eastman Chemical Co. have a much lower P/E of 15.68 and EV to EBITDA of 10.37, highlighting the disparity in valuation. Additionally, Avient Corp.'s recent stock performance has been underwhelming, with a year-to-date return of -20.14% compared to the S&P 500's positive return of 15.47%, and a one-year return of -32.11% against the S&P 500's 16.90%. This further reinforces the notion that the stock is not only overvalued but also struggling in the market....
Read More
Avient Corp. Experiences Revision in Its Stock Evaluation Amidst Market Challenges
Avient Corp., a small-cap company in the Chemicals & Petrochemicals sector, has experienced a valuation adjustment, with a notably high P/E ratio and premium price-to-book value. The company's stock has declined significantly over the past year, contrasting with broader market gains, raising questions about its competitive position.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 93 Schemes (58.18%)
Held by 128 Foreign Institutions (11.52%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 4.83% vs 10.73% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 368.84% vs -141.03% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 3.11% vs -7.48% in Dec 2023
YoY Growth in year ended Dec 2024 is 123.72% vs -8.18% in Dec 2023






